Review article
Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease

https://doi.org/10.1016/S0022-2143(98)90180-9Get rights and content

Abstract

At present, the only iron (Fe) chelator in clinical use for the treatment of Fe overload disease is the tris-hydroxamate deferoxamine (DFO). However, DFO suffers from a number of disadvantages, including the need for subcutaneous infusion (12 to 24 hours a day, 5 or 6 times per week), its poor intestinal absorption, and high cost. Therefore, there is an urgent need for an efficient, economical, and orally effective Fe chelator. Pyridoxal isonicotinoyl hydrazone (PIH) is a tridentate Fechelating agent that shows high Fe chelation efficacy both in vitro in cell culture models and also in vivo in rats and mice. In addition, this chelator is relatively non-toxic, economical to synthesize, and orally effective, and it shows high selectivity and affinity for Fe. However, over the last 10 years the development of PIH and its analogs has largely been ignored because of justifiable interest in other ligands such as 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Unfortunately, recent clinical trials have shown that significant complications occur with L1 therapy, and it is controversial whether this chelator is effective at reducing hepatic Fe levels in patients. Because of the current lack of a clinically useful Fe chelator to replace DFO, PIH and its analogs appear to be potential candidate compounds that warrant further investigation. In this review we will discuss the studies that have been performed to characterize these chelators at the chemical and biologic levels as effective agents for treating Fe overload. The evidence from the literature suggests that these ligands deserve further careful investigation as potential orally effective Fe chelators.

References (78)

  • A Aruffo et al.

    Structural studies of Fe(III) and Cu(II) complexes of salicylaldehyde benzoyl hydrazone, a synthetic chelating agent exhibiting diverse biological properties

    Inorganica Chim Acta

    (1982)
  • TB Murphy et al.

    Structural studies of iron(III) complexes of the new iron-binding drug pyridoxal isonicotinoyl hydrazone

    Inorg Chim Acta

    (1982)
  • DR Richardson et al.

    Iron chelators of the pyridoxal isonicotinoyl hydrazone class part 1. Ionisation characteristics of the ligands and their relevance to biological properties

    Inorganica Chim Acta

    (1990)
  • E Baker et al.

    Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture

    Biochem Pharmacol

    (1985)
  • DR Richardson et al.

    The release of iron and transferrin from the human melanoma cell

    Biochim Biophys Acta

    (1991)
  • AR Huang et al.

    A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe

    Biochim Biophys Acta

    (1983)
  • DR Richardson

    Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process

    Biochim Biophys Acta

    (1997)
  • P Ponka et al.

    Iron utilization in rabbit reticulocytes

  • ML Adams et al.

    The effects of inhibition of heme synthesis on the intracellular localisation of iron in rat reticulocytes

    Biochim Biophys Acta

    (1989)
  • DR Richardson et al.

    Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates of iron metabolism

    Blood

    (1996)
  • EH Morgan

    Chelator-mediated iron efflux from reticulocytes

    Biochim Biophys Acta

    (1983)
  • AM Fredenburg et al.

    The pharmacokinetics and blood brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat

    Toxicology

    (1996)
  • P Ponka et al.

    Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes

    Biochim Biophys Acta

    (1988)
  • DL Bakkeren et al.

    Release of iron from endosomes is an early step in the transferrin cycle

    Int J Biochem

    (1987)
  • RC Hider

    Potential protection from toxicity by oral iron chelators

    Toxicol Lett

    (1995)
  • B Modell et al.

    The clinical approach to thalassemia

    (1984)
  • RD Propper et al.

    Continuous subcutaneous administration of desferrioxamine in patients with iron overload

    N Engl J Med

    (1977)
  • NF Olivieri

    Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major [abstract]

    Blood

    (1996)
  • NF Olivieri

    Long-term follow-up of body iron in patients with thalassemia major during therapy with the orally active iron chelator deferiprone (L1) [abstract]

    Blood

    (1996)
  • A Florence et al.

    Oral iron chelators may do more harm than good

  • FN al Refaie et al.

    Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators

    Br J Haematol

    (1995)
  • FN al Refaie et al.

    Deferiprone-associated myelotoxicity

    Eur J Haematol

    (1994)
  • MJ Kersten et al.

    Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial

    Ann Hematol

    (1996)
  • A Castriota-Scanderbeg et al.

    Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)

    Br J Haematol

    (1997)
  • GJ Kontoghiorghes

    The design of orally active iron chelators for the treatment of thalassemia

  • NF Olivieri et al.

    Iron chelation therapy with oral deferiprone in patients with thalassemia major

    N Engl J Med

    (1995)
  • HM Schulman et al.

    In vitro anti-oxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone and some of its analogs

    Redox Report

    (1996)
  • DR Richardson

    The potential of iron chelators as effective antiproliferative agents

    Can J Physiol Pharmacol

    (1997)
  • Cited by (129)

    View all citing articles on Scopus

    Supported by operating grants from the Medical Research Council of Canada (D.R.R. and PP.), a Terry Fox New Investigator Award from the National Cancer Institute of Canada (D.R.R.), and the National Health and Medical Research Council of Australia (D.R.R). D.R.R. was the recipient of a Medical Research Council of Canada Scholarship.

    View full text